# Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer

> **NCT00363285** · PHASE3 · UNKNOWN · sponsor: **St. Bartholomew's Hospital** · enrollment: 900 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** gonadotrophin releasing hormone
- **DRUG:** cyproterone acetate
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00363285
- **Lead sponsor:** St. Bartholomew's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363285, "Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00363285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*